Abstract:
A distance of flight (DOF) approach to mass spectroscopy in which the resolution among the various ion masses is accomplished in space rather than time. A separate detector is associated with each ion mass resolution element. The DOF mass spectrometer can serve as one element in a tandem arrangement which has the capability to produce a full two-dimensional precursor/product spectrum for each bunch of ions extracted from the source. A "distance-of-flight" (DOF) mass analyzer is used in combination with time-of-flight (TOF) mass analysis for precursor and product dispersion. All the precursor ions can undergo a mass changing reaction simultaneously, while still retaining the essential information about the particular precursor m/z value from which each product m/z value emanated. Through the use of a two-dimensional detector, all the products ions from all the precursors can be detected for each batch of ions analyzed.
Abstract:
The present invention provides probes for the human papillomaviruses HPV-18, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-58, HPV-59, HPV-68 (ME180), MM4/W13B and MM9/PAP238A which hybridize with the homologous regions of these HPVs' DNA. The present invention also provides probes for these human papillomaviruses which are capable of hybridizing with newly discovered variant regions of these HPVs' DNA.
Abstract:
A Hardware-Embedded Delay Physical Unclonable Function ("HELP PUF") leverages entropy by monitoring path stability and measuring path delays from core logic macros. Reliability and security enhancing techniques for the HELP PUF reduce bit flip errors during regeneration of the bitstring across environmental variations and improve cryptographic strength along with the corresponding difficulty of carrying out model building attacks. A voltage-based enrollment process screens unstable paths on normally synthesized (glitchy) functional units and reduces bit flip errors by carrying out enrollment at multiple supply voltages controlled using on-chip voltage regulators.
Abstract:
resumo "bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados", por tratar-se a presente invenção de protocélulas para direcionamento específico para células hepatocelulares e outras células cancerígenas, que compreendem um núcleo de sílica nanoporosa com uma bicamada lipídica suportada; pelo menos um agente que facilita a morte da célula cancerígena (tal como uma molécula pequena tradicional, uma carga macromolecular (por exemplo, siarn ou uma toxina protéica, como, por exemplo, toxina ricina de cadeia a ou toxina difteria de cadeia a) e/ou um dna plasmídeo empacotado com uma histona disposta no interior do núcleo de sílica nanoporosa (de preferência, super-enrolado, de modo a empacotar de forma mais eficiente o dna nas protocélulas), que é opcionalmente modificado por uma sequência de localização nuclear, para auxiliar na localização das protocélulas dentro do núcleo da célula cancerígena e a capacidade de expressar os peptídeos envolvidos na terapia (apoptose/morte celular) das células cancerígenas ou como repórter, um peptídeo de direcionamento que tem como alvo as células cancerígenas no tecido a ser tratado, de tal modo que a ligação da protocélula às células-alvo é específica e aprimorada e um peptídeo fusogênico que promove o escape endossomal das protocélulas e do dna encapsulado. as protocélulas, de acordo com a presente invenção, podem ser utilizadas para tratar o câncer, incluindo, especialmente, o câncer hepatocelular (câncer de fígado), por meio do uso dos novos peptídeos de ligação (peptídeos c-met), que se ligam seletivamente a um tecido hepatocelular, ou para funcionar no diagnóstico do câncer, incluindo o tratamento do câncer e a descoberta de medicamentos. 1/1
Abstract:
A method of preparing M-N-C catalysts utilizing a sacrificial support approach and inexpensive and readily available polymer precursors as the source of nitrogen and carbon is disclosed. Exemplary polymer precursors include non-porphyrin precursors with no initial catalytic activity. Examples of suitable non-catalytic non-porphyrin precursors include, but are not necessarily limited to low molecular weight precursors that form complexes with iron such as 4-aminoantipirine, phenylenediamine, hydroxysuccinimide, ethanolamine, and the like.
Abstract:
The Distribution Effect is proposed for the HELP PUF that is based on purposely introducing biases in the mean and range parameters of path delay distributions to enhance entropy. The biased distributions are then used in the bitstring construction process to introduce differences in the bit values associated with path delays that would normally remain fixed. Offsets are computed to fine tune a token's digitized path delays as a means of maximizing entropy and reproducibility in the generated bitstrings: a first population-based offset method computes median values using data from multiple tokens (i.e., the population) and a second chip-specific technique is proposed which fine tunes path delays using enrollment data from the authenticating token.
Abstract:
Embodiments of the present invention provide a system and method for analyzing a plurality of samples comprising obtaining with an autoampler a plurality of samples from a first plate having a plurality of sample wells wherein the autosampler has a plurality of probes for sampling a set of samples and wherein each probe of the plurality of probes is in communication with a separate flow cytometer via a separate conduit. The plurality of samples comprising particles is moved into a fluid flow stream for each separate conduit. Adjacent ones of the plurality of samples are separated from each other in the fluid flow stream by a separation gas, thereby forming a gas-separated fluid flow stream. The gas-separated fluid flow stream is independently guided to and through each separate flow cytometer.
Abstract:
This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.